MedTrace Logo

Bioavailability Study of Ondansetron 16 mg Orally Disintegrating Tablets Under Fasting Conditions

NCT00659685 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2008-04-16

No results posted yet for this study

Summary

Single-dose cross over comparative bioavailability of Ondansetron 16 mg ODT and Zofran 16 mg ODT

Conditions

  • Healthy

Interventions

DRUG

Ondansetron

ODT, single-dose, fasting

DRUG

Zofran ODT

Sponsors & Collaborators

  • Algorithme Pharma Inc

    collaborator INDUSTRY

  • Par Pharmaceutical, Inc.

    lead INDUSTRY

Principal Investigators

  • Christian Aumais · Algotithme Pharma Inc

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-11-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00659685 on ClinicalTrials.gov